We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Calyxt Inc | NASDAQ:CLXT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.30 | 6.30 | 7.00 | 0 | 01:00:00 |
Q3 High Oleic Soybean Product Revenue of $3 Million Represents Highest in Company History
Reiterates 2019 Annual Revenue Guidance of $7 Million to $8 Million
Operational Savings Expected to Extend Cash Runway to Mid-2021
Over 70,000 2020 Acres Contracted as of October 31, 2019
Calyxt, Inc. (NASDAQ: CLXT), a plant-based technology company focused on healthy food ingredients, has reported results for its third quarter ended September 30, 2019.
Key Third Quarter and Subsequent Highlights
Management Commentary
“The third quarter of 2019 was marked by a highly encouraging level of market acceptance and growing interest for our proprietary High Oleic, premium soybean oil and our first commercial product,” said Jim Blome, Chief Executive Officer. “We are expanding our geographic footprint and generating weather-risk diversity by growing 2020 acres, bringing five new varieties to market and adding Landus’ seed distribution and agronomy support for our High Oleic Soybeans.
“The TALEN® technology, which powers our innovation platform, is particularly exciting, allowing us to produce a plant that is based on precise and targeted changes to its natural genome. With our established processes we can develop a healthier food ingredient in a short amount of time relative to other development processes. Moreover, we believe we have an exciting product pipeline that we intend to advance over time either through our own commercial organization or in collaboration with other industry participants with established market access and scale,” continued Blome.
“Following our successful completion of a voluntary consultation with the Food and Drug Administration in February 2019, we launched our first commercial product, Calyno, which is a High Oleic Soybean Oil with zero grams of trans fat per serving, a reduced saturated fat content, low polymerization levels, and other unique benefits that make it particularly attractive in multiple food manufacturing and foodservice applications.
“Additionally, one of the world’s largest food service distributors, Sysco, took notice of the strong introduction and currently stocks and sells Calyno to its customers. Sysco’s customer count is now above 60 as commercial kitchens recognize the ROI possibilities that our oil can bring to their bottom line with up to 3X fry life and less varnish compared to commodity oils. Our research indicates that oil is one of the largest drivers of food costs in many restaurants and that the foodservice oil market is a $7.6 billion market segment, representing a large addressable market. We also see progress with food manufacturing, as large-scale industry participants accelerate their testing of specific applications of our oil. This $4.7 billion market segment is particularly appealing because our technology can deliver key characteristics like high stability, long shelf life and low polymerization,” explained Blome.
“To power Calyno’s growth trajectory, we have built out our supply chain – partnering with nearly 175 farmers in the Upper Midwest to grow our proprietary soybeans. Our collaboration with Agtegra, a farmer-owned grain and agronomy cooperative with more than 6,300 active member-owners in eastern North and South Dakota commenced in early 2019 and positions Calyxt with seed distribution, agronomy support, grain storage and transportation services. During the third quarter, we engaged Landus to increase our geographic footprint for acres by adding their seed distribution, agronomy support, grain storage and transportation services in Iowa. With the addition of Landus to our geographic footprint, we now have reach to 40% of the soybean acres grown in the United States. Based on these developments and our current progress, we are reiterating our 100,000 contracted acre target for 2020, up from 36,000 planted acres in 2019.
“We continue to drive our R&D pipeline and expand it to include R&D exploration in canola, hemp, oats, peas, peanuts, potatoes, soybeans and wheat, which advances our leadership position as an innovation platform. We also expanded our go-to-market strategy by seeking to develop collaborations with third parties for that innovation. We anticipate these collaborations will deliver new revenue streams and will drive the monetization of our technology platform,” said Blome.
“From an operating perspective, we have assembled a strong leadership team to drive the business and are adding strategic hires to the team. We are seeing additional revenue opportunities as well as strategic opportunities for our product pipeline. We are excited to deliver healthier food and food ingredients to consumers and I look forward to leveraging our first-mover advantage and cutting-edge technology to create long-term, sustainable value for our shareholders,” concluded Blome.
Third Quarter 2019 Financial Results
“I am pleased with our cash usage trajectory in the third quarter of 2019,” added Bill Koschak, Chief Financial Officer of Calyxt. “We have largely completed investing in our G&A platform required to scale the organization. Future investments are expected to be in R&D as we grow our pipeline and collaboration projects, and in sales, supply chain, quality and food safety to support growth in our soybean product lines. We reiterate our prior FY2019 financial guidance of $7 million to $8 million in revenue and $3 million to $3.25 million in cash usage per month.
“Taking into account our anticipated usage going forward, including operational savings we have identified, I believe our cash position will be sufficient to fund operations to mid-2021,” concluded Koschak.
Third Quarter 2019 Results Conference Call
Calyxt, Inc. will hold a conference call today at 4:30 p.m. Eastern time to discuss its results for the third quarter ended September 30, 2019. Chief Executive Officer Jim Blome, Chief Financial Officer Bill Koschak, Chief Business Development and Supply Chain Officer Manoj Sahoo, Chief Technology Officer Dr. Travis Frey, and Senior Vice President of Sales & Marketing Keith Blanks will host the conference call, followed by a question and answer session.
To access the call, please use the following information:
Date:
Wednesday, November 6, 2019
Time:
4:30 p.m. EST, 1:30 p.m. PST
US & Canada dial-in number:
+1 (877) 407-9747
International dial-in number:
+1 (412) 902-0044
Conference ID:
13695884
Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have difficulty connecting with the conference call, please contact MZ Group at +1 (949) 491-8235.
The conference call will be broadcast live and available for replay at https://bit.ly/35StOWl and via the investor relations section of the Company’s website here.
A replay of the call will be available for one month following the conference call.
Toll Free Replay Number:
+1 (877) 660-6853
International Replay Number:
+1 (201) 612-7415
Replay ID:
13695884
About Calyxt
Calyxt (NASDAQ: CLXT) is a plant-based technology company that utilizes our patented technology to “Make The Food You Love A Healthier Choice™”. The care we take extends beyond nutritional value. We partner with farmers and food companies to deliver traceable plant-based products developed to be healthier and more sustainable than their conventional counterparts. We use cutting edge plant breeding techniques to develop products that help improve diets. We continuously pursue innovation to deliver good food that is good for you.
Calyxt is located in Roseville, MN and is listed on the NASDAQ market (ticker: CLXT). For further information, please visit our website at www.calyxt.com.
Use of Non-GAAP Financial Information
To supplement our unaudited financial results prepared in accordance with GAAP, we present Adjusted EBITDA, which is not a measure defined by GAAP. We define Adjusted EBITDA as Net Loss excluding Interest, net, Income tax expense, Depreciation and Amortization expense, Stock-based compensation, Payroll tax benefits that are no longer realizable, Section 16 officer transition expenses and Forward Purchase Contract gains and losses. We provide in the table below a reconciliation of Net Loss to Adjusted EBITDA, which is the most directly comparable GAAP financial measure. Adjusted EBITDA is not meant to be considered in isolation or as a substitute for financial information presented in accordance with GAAP, and Adjusted EBITDA should be viewed as supplemental and in addition to Net Loss. Investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures, which exclude charges that have an effect on our reported financial results. In addition, other companies may report Adjusted EBITDA or similarly titled measures but calculate them differently, which reduces their usefulness as a comparative measure.
Because Adjusted EBITDA excludes non-cash items and discrete or infrequently occurring items, we believe that Adjusted EBITDA provides investors with useful supplemental information about the operational performance of our business and facilitates comparison of our financial results between periods where certain items may vary significantly independent of our business performance. Moreover, our presentation of Adjusted EBITDA enhances transparency because our management team utilizes this metric in evaluating, and making operational decisions, regarding our business.
The tables below present a reconciliation of Net Loss to Adjusted EBITDA:
Three months ended
September 30,
In Thousands
2019
2018
Net loss (GAAP measure)
$
(10,669)
$
(7,483)
Non-GAAP adjustments:
Stock-based compensation
2,705
589
Interest, net
(32)
(228)
Income tax expense
—
—
Depreciation & amortization
362
356
Payroll tax benefits that are no longer realizable
536
(40)
Section 16 officer transition expenses
193
374
Loss on Forward Purchase Contracts
—
50
Adjusted EBITDA
$
(6,905)
$
(6,382)
Nine months ended
September 30,
In Thousands
2019
2018
Net loss (GAAP measure)
$
(27,477)
$
(19,429)
Non-GAAP adjustments:
Stock-based compensation
6,565
3,016
Interest, net
(296)
(88)
Income tax expense
—
—
Depreciation & amortization
1,051
727
Payroll tax benefits that are no longer realizable
411
(48)
Section 16 officer transition expenses
1,054
374
Loss on Forward Purchase Contracts
—
413
Adjusted EBITDA
$
(18,692)
$
(15,035)
Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” the negative of these terms and other comparable terminology. These forward-looking statements, which are subject to risks, uncertainties and assumptions about us, may include projections of our future financial or operating performance, our anticipated product pipeline, collaboration or growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements, including those factors discussed under the caption entitled “Risk Factors” in our Annual Report on Form 10-K, along with our other filings with the U.S. Securities and Exchange Commission. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by applicable laws.
Certain market and industry data and forecasts included in this press release were obtained from independent market research, industry publications and surveys, governmental agencies and publicly available information. We believe the data from such third-party sources to be reliable. However, we have not independently verified any of such data and cannot guarantee its accuracy or completeness. Similarly, internal market research and industry forecasts, which we believe to be reliable based upon our management's knowledge of the market and the industry, have not been verified by any independent sources. While we are not aware of any misstatements regarding the market or industry data presented herein, our estimates involve risks and uncertainties and are subject to change based on various factors, including those discussed under the caption entitled “Risk Factors” in our Annual Report on Form 10-K, along with our other filings with the U.S. Securities and Exchange Commission.
CALYXT, INC.
BALANCE SHEETS
(In Thousands, Except Par Value and Share Amounts)
September 30,
2019
(unaudited)
December 31,
2018
Assets
Current assets:
Cash and cash equivalents
$
66,434
$
93,794
Restricted cash
381
381
Trade accounts receivable
1,304
—
Due from related parties
69
46
Inventory
2,371
—
Prepaid expenses and other current assets
1,109
1,301
Total current assets
71,668
95,522
Non-current restricted cash
1,135
1,113
Land, buildings, and equipment
23,337
21,850
Other non-current assets
270
306
Total assets
$
96,410
$
118,791
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable
$
945
$
818
Accrued expenses
1,958
2,007
Accrued compensation and benefits
1,783
1,305
Due to related parties
705
1,905
Current portion of financing lease obligations
349
258
Other current liabilities
51
711
Total current liabilities
5,791
7,004
Financing lease obligations
18,331
18,227
Other non-current liabilities
159
163
Total liabilities
24,281
25,394
Stockholders’ equity:
Common stock, $0.0001 par value; 275,000,000 shares authorized; 32,926,312 shares issued and 32,867,413 shares outstanding as of September 30, 2019, and 32,664,429 shares issued and 32,648,893 shares outstanding as of December 31, 2018
3
3
Additional paid-in capital
182,948
176,069
Common stock in treasury, at cost; 58,899 shares
(875
)
(230
)
Accumulated deficit
(109,892
)
(82,445
)
Accumulated other comprehensive loss
(55
)
—
Total stockholders’ equity
72,129
93,397
Total liabilities and stockholders’ equity
$
96,410
$
118,791
CALYXT, INC.
STATEMENTS OF OPERATIONS
(Unaudited and in Thousands Except Shares and Per Share Amounts)
Three Months Ended
September 30,
Nine months ended
September 30,
2019
2018
2019
2018
Revenue
$
2,967
$
27
$
3,533
$
234
Operating expenses:
Cost of revenue
3,528
—
3,865
—
Research and development
3,579
3,440
8,536
7,850
Selling, general and administrative
6,248
3,311
17,723
9,914
Management fees and royalties
305
975
1,117
1,957
Total operating expenses
13,660
7,726
31,241
19,721
Loss from operations
(10,693
)
(7,699
)
(27,708
)
(19,487
)
Interest, net
32
228
296
88
Foreign currency transaction loss
(8
)
(12
)
(35
)
(30
)
Loss before income taxes
(10,669
)
(7,483
)
(27,447
)
(19,429
)
Income taxes
—
—
—
—
Net loss
$
(10,669
)
$
(7,483
)
$
(27,447
)
$
(19,429
)
Basic and diluted loss per share
$
(0.32
)
$
(0.23
)
$
(0.84
)
$
(0.65
)
Weighted average shares outstanding - basic and diluted
32,866,467
32,381,010
32,759,194
30,040,926
CALYXT, INC.
STATEMENTS OF CASH FLOWS
(Unaudited and in Thousands)
Nine months ended September 30,
2019
2018
Operating activities
Net loss
$
(27,447
)
$
(19,429
)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
1,051
727
Stock-based compensation
6,565
3,016
Unrealized foreign exchange gain
—
12
Changes in operating assets and liabilities:
Trade accounts receivable
(1,304
)
—
Due to/from related parties
(1,223
)
576
Inventory
(2,371
)
—
Prepaid expenses and other assets
192
(341
)
Accounts payable
127
355
Accrued expenses
(49
)
880
Accrued compensation and benefits
478
70
Other accrued liabilities
(743
)
518
Other non-current assets
36
16
Net cash used by operating activities
(24,688
)
(13,600
)
Investing activities
Purchases of land, buildings and equipment
(2,538
)
(830
)
Net cash used by investing activities
(2,538
)
(830
)
Financing activities
Costs incurred related to the issuance of stock
—
(222
)
Proceeds from issuance of common stock
—
57,706
Repayments of financing lease obligations
(195
)
—
Proceeds from the exercise of stock options
314
2,128
Costs incurred related to shares withheld for net share settlement
(645
)
—
Proceeds from the sale and leaseback of land, buildings, and equipment
414
—
Net cash (used) provided by financing activities
(112
)
59,612
Net (decrease) increase in cash, cash equivalents and restricted cash
(27,338
)
45,182
Cash, cash equivalents and restricted cash - beginning of period
95,288
56,664
Cash, cash equivalents and restricted cash - end of period
$
67,950
$
101,846
View source version on businesswire.com: https://www.businesswire.com/news/home/20191106005896/en/
Calyxt Media Contact: Trina Lundblad, Director of Corporate Communications (612) 790-0514 media@calyxt.com
Calyxt Investor Relations Contact: Chris Tyson Managing Director MZ Group – MZ North America (949) 491-8235 CLXT@mzgroup.us www.mzgroup.us
1 Year Calyxt Chart |
1 Month Calyxt Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions